Virobay Facts

2014 – Virobay to present data on two Cathepsin S inhibitor programs in neuropathic pain and Alzheimer's disease at the 2014 Society for Neuroscience Annual Meeting more

2014 – Virobay completes $8 million Series B preferred stock financing more

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

more

News - Archive

December 5, 2012

Cathepsin S, Virobay’s lead drug candidate, was selected by Windhover as one of the top 10 most interesting inflammatory/autoimmune projects available for partnering.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive anti-inflammatory/autoimmune opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence.

"Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

Link to presentation "Cathepsin S Inhibitors for the Treatment of Inflammatory Bowel Disease"